GlassScriptPhysician profile
Ashley M Bridges
NPI 1487944427
$2,362.58
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,181 · 2020: $354 · 2021: $13.72 · 2022: $241 · 2023: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $572.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $317.94 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $241.02 | 2019-2022 | |
| Abbvie INC. | $222.01 | 2022-2023 | Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $182.68 | 2019-2020 | |
| Pfizer INC. | $149.54 | 2019-2023 | |
| Amgen INC. | $119.05 | 2019-2022 | |
| Lilly USA, LLC | $116.20 | 2019-2023 | Mounjaro, Trulicity, Jardiance |
| Teva Pharmaceuticals USA, INC. | $108.61 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.64 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $96.85 | 2019-2023 | |
| Astellas Pharma US INC | $95.33 | 2019-2023 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $94.74 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.84 | 2019-2023 | Trintellix |
| Allergan, INC. | $69.55 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $59.10 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.78 | 2019-2023 | Trulance, Xifaxan |
| Otsuka America Pharmaceutical, INC. | $43.19 | 2023 | Rexulti |
| Antares Pharma, INC. | $30.54 | 2019-2020 | |
| Horizon Therapeutics Plc | $29.25 | 2022 | |
| Corium, LLC | $24.20 | 2022 | |
| Medtronic, INC. | $20.87 | 2023 | Intellis Adaptivestim |
| Supernus Pharmaceuticals, INC. | $19.35 | 2019 | |
| Xeris Pharmaceuticals, INC. | $16.44 | 2023 | Gvoke Hypopen |
| Radius Health, INC. | $16.21 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.52 | 2022 | |
| Dexcom, INC. | $11.95 | 2022 | |
| Ironshore Pharmaceuticals INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Bridges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.